Advertisement


Jens Marquardt, MD, and Jens Hoeppner, MD, on Esophageal Cancer: Phase III Findings on Chemotherapy vs Chemoradiation

2024 ASCO Annual Meeting

Advertisement

Jens Marquardt, MD, of the University of Lübeck, and Jens Hoeppner, MD, of the University of Bielefeld, discuss findings from the ESOPEC trial, which showed that perioperative chemotherapy (fluorouracii, leucovorin, oxaliplatin, docetaxel) and surgery improves survival in patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation (41.4 Gy plus carboplatin and paclitaxel) followed by surgery (LBA1).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Marquardt: Good morning and thank you very much for being here today. It's a great pleasure to have you here and talk about the ESOPEC trial that you are presenting at this year's ASCO. Do you want to start out by just simply explaining why you actually did this trial to start with? Hoeppner: Locally advanced esophageal adenocarcinoma is usually treated in a multimodality treatment I've seen. And we've seen that both neoadjuvant chemoradiation and perioperative chemotherapy were superior to surgery alone. That has been stated in different trials, but there is no head-to-head comparison. So we don't know what to recommend to our patients, either neoadjuvant chemoradiation, or perioperative chemotherapy. And ESOPEC is the first head-to-head comparison of the recent protocols of perioperative chemotherapy, namely FLOT, and the recent protocol of neoadjuvant chemoradiation, namely CROSS. Marquardt: I think that makes a lot of sense. Can you tell us what the setup of the study was? How many sites were involved, how you approached everything? Hoeppner: ESOPEC was carried out between the years 2016 and 2020 in Germany. With overall 25 participating sites. We've enrolled 438 patients, and we've done follow up until 2023. Marquardt: Quite a big study. Right? Hoeppner: Yeah. Marquardt: Very, very nice. And can you tell us the key results and the key implications that you had from this trial? Hoeppner: In our trial, the primary endpoint was overall survival, and secondary endpoints were complications and adverse events from both treatment teams. And we found in the primary endpoint superiority of FLOT over CROSS with a hazard ratio of 0.7. That means after three years, the patients in the FLOT group had a survival benefit of 30% compared to CROSS. Marquardt: When you think about the key results, do you think there's anything that is particularly worth mentioning with regards to the toxicity or when you compare CROSS versus FLOT? Hoeppner: We have found nearly equal complication rates after surgery for both groups. And we have not, the complete adverse events shows that toxicity will be, as an endpoint we haven't addressed completely yet, but it looks like that we have quite equipoise in larger than grade three adverse events. Marquardt: And the surgery was similarly achieved in both arms? So there was no difference. Hoeppner: Yes, no difference in surgeries. Marquardt: I think that is very important, right? For such a trial. When you further think about implications of the trial, what's your, I mean, the overall in general key take messages that you have from the trial? Hoeppner: With the results from ESOPEC, we have a first statement that perioperative chemotherapy is superior to neoadjuvant chemoradiation, and I think we should recommend this to our patients and recommend perioperative chemotherapy with the FLOTS team for treatment of locally advanced resectable esophageal adenocarcinoma. Marquardt: This really is practice changing, right? So I assume that the radiation oncologist would have lots of questions to you with regards to the trial. In the design of the trial, did you account for differences in radiation or was that all investigator's choice or how was that adjusted? Hoeppner: The radiation scene was CROSS. This is established, or it was published in 2012 by a Dutch group. And this became the standard of care in Germany where the trial took place. And the participating centers were all university medical centers and large tertiary referral centers. So that this team was very established in the moment ESOPEC took place and therefore it was a standard of care in university medical centers in Germany and as participating centers. Marquardt: All experienced centers? Hoeppner: Yes. Marquardt: So more or less comparable approaches. Hoeppner: Yeah. Marquardt: Very, very nice. Thank you very much for being here today and sharing your insights into this beautiful study. Congratulations and yeah, good luck. Hoeppner: Thank you very much. Yes.

Related Videos

Colorectal Cancer

Jeanne Tie, MD, MBChB, on Colon Cancer: New Data on ctDNA Guiding Adjuvant Therapy

Jeanne Tie, MD, MBChB, of Peter MacCallum Cancer Centre, discusses data on survival and updated 5-year results from the DYNAMIC trial, which supports a role for circulating tumor DNA (ctDNA) analysis, including serial sampling, in the management of patients with stage II colon cancer (Abstract 108).

Kidney Cancer

Toni K. Choueiri, MD, FASCO, on RCC: Biomarker Analysis From the CLEAR Trial

Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as geneexpression signatures for tumorinduced proliferation, PDL1 status, or the mutation status of RCC driver genes.

Gynecologic Cancers

Mostafa Eyada, MD, on Oral Cyclophosphamide Plus Bevacizumab in Recurrent Ovarian Cancer

Mostafa Eyada, MD, of The University of Texas MD Anderson Cancer Center, discusses study results showing that bevacizumab in combination with oral cyclophosphamide had a response rate of 40% in patients with recurrent platinum-resistant high-grade ovarian cancer (Abstract 5517).

Multiple Myeloma

Amrita Y. Krishnan, MD, and Paula Rodríguez-Otero, MD, PhD, on Multiple Myeloma: Findings From the PERSEUS Trial on a Regimen for Transplant-Eligible Patients

Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, and Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, discuss data that appear to further support daratumumab plus bortezomib, lenalidomide, and dexamethasone as a new standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (Abstract 7502).

Multiple Myeloma

Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib

Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lenalidomide, and dexamethasone deepened responses and increased the rate of measurable residual disease negativity vs isatuximab with lenalidomide and dexamethasone in patients with newly diagnosed transplant-ineligible multiple myeloma (Abstract 7501).

Advertisement

Advertisement




Advertisement